U.S. Life Science & Diagnostic Tools: 2Q'26 Insider Transactions: Much More Selling vs. Buying; AVTR Remains Only Open Market Buyer

Research evidence excerpt

U.S. Life Science & Diagnostic Tools: 2Q'26 Insider Transactions: Much More Selling vs. Buying; AVTR Remains Only Open Market Buyer

Equity Research

8 July 2026

U.S. Life Science & Diagnostic Tools

2Q'26 Insider Transactions: Much

More Selling vs. Buying; AVTR

U.S. Life Science & Diagnostic ToolsRemains Only Open Market Buyer

POSITIVE

We analyzed 2Q'26 insider transactions for our coverage and U.S. Life Science & Diagnostic Tools

Luke Sergottsaw greater selling activity ($410M/2.9M shares sold in

aggregate, including pre-scheduled). Only AVTR and DGX +1luke.sergott@barclays.com212 526 9258

insiders purchased stock in the open market, while ILMN and BCI, US

GH saw the largest open market sales. Anna Kruszenski

+1 212 526 0134

anna.kruszenski@barclays.com

While we acknowledge that some of the names that saw open market sales of scale partially BCI, US

reflected exercise/conversion of derivatives, there were still a sizable amount of true open Salem Salem

market sales. Notably, this marks the fifth consecutive quarter of AVTR insiders purchasing +1 212 526 3431

shares in the open market. We continue to think this is a signal from new management on their salem.salem@barclays.com

confidence in restructuring/turning the business around, especially given the broader lack of BCI, US

insider share purchases across the rest of the space. Overall, insiders purchased <$1M worth of Jacob Putman, CFA

stock in the open market during 2Q, vs. $322M of total open market sales. +1 212 526 5704

jacob.putman@barclays.com

Analyzing 2Q'26 Open Market Insider Transactions BCI, US

Quantitative Portfolio StrategyWe analyzed 2Q'26 insider buying and selling activity for companies in our Life Science &

Jingling Guan(v)Diagnostic Tools coverage universe.